Cytori Therapeutics (CYTX) Given a $4.00 Price Target at Maxim Group

Maxim Group set a $4.00 price objective on Cytori Therapeutics (NASDAQ:CYTX) in a research note issued to investors on Tuesday, February 13th. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also commented on CYTX. B. Riley reiterated a hold rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th. Zacks Investment Research lowered Cytori Therapeutics from a hold rating to a sell rating in a research report on Thursday, November 9th. Finally, ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $2.30.

Shares of Cytori Therapeutics (NASDAQ:CYTX) traded up $0.01 during mid-day trading on Tuesday, hitting $0.34. The stock had a trading volume of 749,800 shares, compared to its average volume of 2,157,192. Cytori Therapeutics has a 1-year low of $0.22 and a 1-year high of $2.08. The stock has a market capitalization of $11.41, a price-to-earnings ratio of -0.38 and a beta of 3.11.

In other news, major shareholder Ag Postfinance sold 236,155 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $0.34, for a total transaction of $80,292.70. Following the completion of the transaction, the insider now directly owns 5,311,451 shares in the company, valued at approximately $1,805,893.34. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total value of $38,000.00. Following the transaction, the insider now owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 695,767 shares of company stock valued at $231,951. 1.90% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after purchasing an additional 275,653 shares in the last quarter. Sabby Management LLC raised its position in shares of Cytori Therapeutics by 28.0% during the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after acquiring an additional 355,504 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its position in shares of Cytori Therapeutics by 134.0% during the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock worth $644,000 after acquiring an additional 1,223,046 shares in the last quarter. 10.41% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Cytori Therapeutics (CYTX) Given a $4.00 Price Target at Maxim Group” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://stocknewstimes.com/2018/02/22/cytori-therapeutics-cytx-given-a-4-00-price-target-by-maxim-group-analysts.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply